Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Development of Biomarkers for Inhibition of SLC6A19 (B0AT1)-A Potential Target to Treat Metabolic Disorders

dc.contributor.authorJaved, Kiran
dc.contributor.authorCheng, Qi
dc.contributor.authorCarroll, Adam
dc.contributor.authorTruong, Thy
dc.contributor.authorBroer, Stefan
dc.date.accessioned2019-04-29T05:46:42Z
dc.date.available2019-04-29T05:46:42Z
dc.date.issued2018
dc.date.updated2019-03-12T07:35:18Z
dc.description.abstractRecent studies have established that dietary protein restriction improves metabolic health and glucose homeostasis. SLC6A19 (B⁰AT1) is the major neutral amino acid transporter in the intestine and carries out the bulk of amino acid absorption from the diet. Mice lacking SLC6A19 show signs of protein restriction, have improved glucose tolerance, and are protected from diet-induced obesity. Pharmacological blockage of this transporter could be used to induce protein restriction and to treat metabolic diseases such as type 2 diabetes. A few novel inhibitors of SLC6A19 have recently been identified using in vitro compound screening, but it remains unclear whether these compounds block the transporter in vivo. To evaluate the efficacy of SLC6A19 inhibitors biomarkers are required that can reliably detect successful inhibition of the transporter in mice. A gas chromatography mass spectrometry (GC-MS)-based untargeted metabolomics approach was used to discriminate global metabolite profiles in plasma, urine and faecal samples from SLC6A19ko and wt mice. Due to inefficient absorption in the intestine and lack of reabsorption in the kidney, significantly elevated amino acids levels were observed in urine and faecal samples. By contrast, a few neutral amino acids were reduced in the plasma of male SLC6A19ko mice as compared to other biological samples. Metabolites of bacterial protein fermentation such as p-cresol glucuronide and 3-indole-propionic acid were more abundant in SLC6A19ko mice, indicating protein malabsorption of dietary amino acids. Consistently, plasma appearance rates of [14C]-labelled neutral amino acids were delayed in SLC6A19ko mice as compared to wt after intra-gastric administration of a mixture of amino acids. Receiver operating characteristic (ROC) curve analysis was used to validate the potential use of these metabolites as biomarkers. These findings provide putative metabolite biomarkers that can be used to detect protein malabsorption and the inhibition of this transporter in intestine and kidney.en_AU
dc.description.sponsorshipThis research was funded by NHMRC, grant number GNT 1128442en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1422-0067en_AU
dc.identifier.urihttp://hdl.handle.net/1885/160750
dc.language.isoen_AUen_AU
dc.provenanceThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en_AU
dc.publisherMDPI Publishingen_AU
dc.relationhttp://purl.org/au-research/grants/nhmrc/1128442
dc.rights© 2018 by the authors. Licensee MDPI, Basel, Switzerlanden_AU
dc.sourceInternational Journal of Molecular Sciencesen_AU
dc.titleDevelopment of Biomarkers for Inhibition of SLC6A19 (B0AT1)-A Potential Target to Treat Metabolic Disordersen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue11en_AU
local.bibliographicCitation.lastpage22en_AU
local.bibliographicCitation.startpage1en_AU
local.contributor.affiliationJaved, Kiran, College of Science, ANUen_AU
local.contributor.affiliationCheng, Qi, College of Science, ANUen_AU
local.contributor.affiliationCarroll, Adam, College of Science, ANUen_AU
local.contributor.affiliationTruong, Thy, College of Science, ANUen_AU
local.contributor.affiliationBroer, Stefan, College of Science, ANUen_AU
local.contributor.authoruidJaved, Kiran, u5941582en_AU
local.contributor.authoruidCheng, Qi, u5436098en_AU
local.contributor.authoruidCarroll, Adam, u4649974en_AU
local.contributor.authoruidTruong, Thy, u4991840en_AU
local.contributor.authoruidBroer, Stefan, u4009041en_AU
local.description.notesImported from ARIESen_AU
local.identifier.absfor060199 - Biochemistry and Cell Biology not elsewhere classifieden_AU
local.identifier.absseo970106 - Expanding Knowledge in the Biological Sciencesen_AU
local.identifier.ariespublicationu4485658xPUB2644en_AU
local.identifier.citationvolume19en_AU
local.identifier.doi10.3390/ijms19113597en_AU
local.identifier.scopusID2-s2.0-85056631293
local.publisher.urlhttps://www.mdpi.com/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Javed_Development_of_Biomarkers_for_2018.pdf
Size:
3.66 MB
Format:
Adobe Portable Document Format